Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 9/20 | 0.37 |
| ▸ | IDH1 | O75874 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | ACACA | Q13085 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097231 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1096676 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1097064 | 0.82 | POLB (0.47) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1106535 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ALMNAMAPK1IDH1 | |
| SCHEMBL10313052 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1096495 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1097203 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL13886836 | 0.80 | F10 (0.33) | F10IDH1ACACBACACAALDH1A1 | |
| SCHEMBL1106541 | 0.79 | F10 (0.40) | SMN1; SMN2KMT2ALMNAMAPK1F10 | |
| SCHEMBL1096165 | 0.79 | F10 (0.40) | SMN1; SMN2KMT2ALMNAMAPK1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | SMN1; SMN2 4168/4885KMT2A 3673/4885LMNA 734/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | SMN1; SMN2 4168/4885KMT2A 3673/4885LMNA 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.